Increased fracture rate in women with breast cancer: A review of the hidden risk

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Body, Jean Jacques ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adjuvant therapy; Aromatase inhibitor; Bisphosphonate; Chemotherapy induced menopause; Osteoporosis; Zoledronic acid

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; RISEDRONIC ACID; STEROID; TAMOXIFEN; ZOLEDRONIC ACID;

BONE ATROPHY; BONE DENSITY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY MENOPAUSE; FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; VERTEBRA FRACTURE; BREAST TUMOR; DRUG EFFECT; FEMALE; OSTEOPOROSIS; PATHOLOGY;

AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 80052078660     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-384     Document Type: Review

References (54)

1. Kanis JA, McCloskey EV, Powles T, Paterson AHG, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181. 10.1038/sj.bjc.6690188, 2362233, 10098755.
2. McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007, 22:135-141.
3. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997, 75:602-605. 10.1038/bjc.1997.105, 2063321, 9052418.
4. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-558. 10.1001/archinte.165.5.552, 15767532.
5. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC, Kilburn LS. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010, 124:153-161. 10.1007/s10549-010-1121-7, 20730486.
6. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141. 10.1016/S1470-2045(10)70257-6, 21087898.
7. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Lang I, Smith I, Gelber RD, Goldhirsch A, Coates AS. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20:1489-1498. 10.1093/annonc/mdp033, 2731016, 19474112.
8. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009, 69:73-82. 10.1016/j.critrevonc.2008.07.013, 18757208.
9. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998, 339:733-738. 10.1056/NEJM199809103391104, 9731089.
10. MacLaughlin EJ, Sleeper RB, McNatty D, Raehl CL. Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2006, 2:281-295. 10.2147/tcrm.2006.2.3.281, 1936264, 18360603.
11. Schurch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996, 11:1935-1942.
12. Anand S, Buch K. Post-discharge symptomatic thromboembolic events in hip fracture patients. Ann R Coll Surg Engl 2007, 89:517-520. 10.1308/003588407X202065, 2048602, 17694599.
13. Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. J Orthop Surg (Hong Kong) 2009, 17:6-9.
14. Margolis DJ, Knauss J, Bilker W, Baumgarten M. Medical conditions as risk factors for pressure ulcers in an outpatient setting. Age Ageing 2003, 32:259-264. 10.1093/ageing/32.3.259, 12720610.
15. Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ, Grunze M, Ziegler R, Leidig-Bruckner G. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998, 8:261-267. 10.1007/s001980050063, 9797911.
16. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006, 11:1121-1131. 10.1634/theoncologist.11-10-1121, 17110632.
17. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127. 10.1016/S1470-2045(07)70003-7, 17267326.
18. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
19. Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007, 34:1551-1560.
20. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521. 10.1001/jama.2009.50, 19190316.
21. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005, 32:589-603. 10.1188/05.ONF.589-603, 15897934.
22. Hadji P, Body JJ, Aapro M, Brufsky A, Coleman R, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416. 10.1093/annonc/mdn164, 18448451.
23. Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, Herzog A, Harris JR. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992, 23:915-923. 10.1016/0360-3016(92)90895-O, 1639653.
24. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990, 61:308-310. 10.1038/bjc.1990.58, 1971401, 2310683.
25. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828. 10.1200/JCO.2005.02.7102, 17159195.
26. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004, 15:323-328. 10.1007/s00198-003-1548-3, 14762652.
27. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis 2008, Washington, DC: National Osteoporosis Foundation, National Osteoporosis Foundation., http://www.nofstore.org/Merchant2/merchant.mvc?Screen=PROD&Product_Code=B120-0708&Category_Code=HPR&Product_Count=0
28. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057. 10.1200/JCO.2003.08.017, 12963702.
29. World Health Organization Prevention and Management of Osteoporosis. Technical Report Series 921 2003, Geneva, Switzerland: World Health Organization, World Health Organization.
30. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 2007, 18:1439-1450. 10.1007/s00198-007-0439-4, 17690930.
31. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995. 10.1007/s001980170006, 11846333.
32. Delmas PD, Fontana A. Bone loss induced by cancer treatment and its management. Eur J Cancer 1998, 34:260-262. 10.1016/S0959-8049(97)10135-6, 9741330.
33. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 2005, 353:2747-2757.
34. Lindsey R, Christiansen C, Einhorn TA, McKay Hart D, Ljunghall S, Mautalen CA, Meunier PJ, Morii H, Mundy GR, Rapado A, Stevenson J. Consensus development statement: who are candidates for prevention and treatment for osteoporosis?. Osteoporos Int 1997, 7:1-6.
35. Lappe JM, Tinley ST. Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked. Cancer 1998, 83:830-834. 10.1002/(SICI)1097-0142(19980901)83:5<830::AID-CNCR2>3.0.CO;2-M, 9731880.
36. Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003, 14:1001-1006. 10.1007/s00198-003-1508-y, 14530912.
37. Dowsett M. Future uses for aromatase inhibitors in breast cancer. J Steroid Biochem Mol Biol 1997, 61:261-266. 10.1016/S0960-0760(97)80021-0, 9365199.
38. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223. 10.1359/jbmr.060508, 16869719.
39. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342. 10.1158/1078-0432.CCR-07-5101, 18829518.
40. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975. 10.1200/JCO.2009.24.5902, 20065185.
41. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882. 10.1200/JCO.2008.16.3832, 18725648.
42. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85. 10.3816/CBC.2009.n.015, 19433387.
43. Llombart A. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (E-ZO-FAST trial). 14th European Cancer Conference (ECCO): 23-27 September 2007 Barcelona, Spain, Abstract 2008.
44. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010, 21:2188-2194. 10.1093/annonc/mdq217, 20444845.
45. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681.
46. Coleman RE, Thorpe HC, Cameron D, Didwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell R. Adjuvant treatment with zoledronic acid in stage II/III breast cancer: the AZURE trial (BIG 01/04). 33rd Annual San Antonio Breast Cancer Symposium: 8-12 December 2010; San Antonio, TX Abstract S4-5.
47. Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004, 164:1108-1112. 10.1001/archinte.164.10.1108, 15159268.
48. Seeman E, Delmas PD. Bone quality -- the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261. 10.1056/NEJMra053077, 16723616.
49. World Health Organization Collaborating Centre for Metabolic Bone Diseases FRAX® WHO Fracture Risk Assessment Tool. World Health Organization Collaborating Centre for Metabolic Bone Diseases., http://sheffield.ac.uk/FRAX/index.jsp
50. Lewiecki EM. Managing osteoporosis: challenges and strategies. Cleve Clin J Med 2009, 76:457-466. 10.3949/ccjm.76a.09019, 19652039.
51. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl 1):S3-18.
52. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011,
53. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046. 10.1007/s00198-007-0343-y, 17323110.
54. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?. Breast Cancer Res Treat 2010, 122:627-636. 10.1007/s10549-010-0935-7, 20490653.